An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Abiomed, Inc. (NASDAQ: ABMD) will release its first-quarter fiscal year 2023 financial results on August 4, 2022. The conference call, hosted by CEO Michael R. Minogue and CFO Todd Trapp, is scheduled for 8:00 a.m. ET. Investors can listen via webcast or by dialing in. A replay will be available until August 11, 2022. Abiomed is known for its innovative medical devices that support heart function and improve blood flow. The company emphasizes growth opportunities, though faces industry and regulatory challenges.
Positive
None.
Negative
Forward-looking statements indicate potential risks, including uncertain regulatory approvals and competition.
Dependence on limited sources of supply may impact operational stability.
DANVERS, Mass.--(BUSINESS WIRE)--
Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/551353819 or dial (888) 330-2413 the international number is (240) 789-2721 conference ID 83972.A replay of this conference call will be available until Thursday, August 11, 2022. The replay phone number is (800) 770- 2030; the international number is (647) 362- 9199.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, including with respect to Abiomed's development of existing and new products, the Company's commercial growth, future business opportunities and pending regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including uncertainties related to the scope, extent and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the possibility of future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological changes, governmental requirements, litigation, future capital requirements and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent filings with the SEC. Readers of this press release are advised not to evaluate forward-looking statements, which reflect information available only as of the date of this release, as reliable information. The Company is under no obligation to release updates to these forward-looking statements to reflect events or circumstances occurring after the date of the release or as a result of the impact of unforeseen events.
